Fundraising Fox
FibroBiologics
NASDAQ: FBLGHouston, US · Founded 2021 · Delaware corporation
Find your way into FibroBiologics
Sign up to see every warm intro you have to FibroBiologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the FibroBiologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
Founders & leadership
FibroBiologics was founded in 2021 by Pete O'Heeron.
PO
Pete O'HeeronChairman/CEO/FounderPete O'Heeron is the founder and CEO of FibroBiologics, a clinical-stage biotech company developing fibroblast cell-based therapies for chronic and degenerative diseases. He has over 25 years of experience in biopharmaceutical development, with more than 400 patents issued or pending in biologics, cell therapy, and medical devices.
JD
Jason D. DavisChief Financial OfficerJason D. Davis has over 25 years of executive and finance experience, including five years at a Big Four accounting firm and roles at PE-backed and public companies where he led two NYSE and two Nasdaq IPOs and raised more than $200 million in public capital markets; he holds a CPA credential.
HK
Hamid KhojaChief Scientific OfficerChief Scientific Officer of FibroBiologics. Khoja has over 25 years of experience leading scientific teams in the development and commercialization of cell-based assays and technologies for clinical, pharmaceutical, and diagnostic applications, with expertise in genomics, proteomics, epigenetics, and NGS platforms.
Board
Reported raises · per SEC filings
Form D private placements$10.7M disclosed across 5 of 6 rounds · 2024–2026
▶$1.2MraisedOct 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedOct 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pete O'HeeronExecutive Officer, Director
- Richard C. CilentoDirector
- Robert HoffmanDirector
- Victoria NiklasDirector
- Kathleen H. RubinsDirector
- Leigh SteinbergDirector
- Jason D. DavisExecutive Officer
- Ruben A. GarciaExecutive Officer
- Hamid KhojaExecutive Officer
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Oct 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$500KraisedSep 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$500KraisedSep 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pete O'HeeronExecutive Officer, Director
- Richard C. CilentoDirector
- Robert HoffmanDirector
- Victoria NiklasDirector
- Kathleen H. RubinsDirector
- Leigh SteinbergDirector
- Jason D. DavisExecutive Officer
- Ruben A. GarciaExecutive Officer
- Hamid KhojaExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$3MraisedJun 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedJun 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
- Robert HoffmanDirector
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Victoria NiklasDirector
- Matthew LinkDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $315K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.7MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert HoffmanDirector
- Matthew LinkDirector
- Stacy CoenDirector
- Jason D. DavisExecutive Officer
- Pete O'HeeronExecutive Officer, Director
- Richard C. CilentoDirector
- Victoria NiklasDirector
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Sales commissions
- $329.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$4MraisedDec 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedDec 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Stacy CoenDirector
- Victoria NiklasDirector
- Matthew LinkDirector
- Robert HoffmanDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedDec 2025 · 4 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedDec 2025 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stacy CoenDirector
- Matthew LinkDirector
- Robert HoffmanDirector
- Victoria NiklasDirector
- Pete O'HeeronExecutive Officer, Director
- Jason D. DavisExecutive Officer
- Richard C. CilentoDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Sales commissions
- $292.2K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as FibroBiologics.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $252K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does FibroBiologics do?
- FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
- Who founded FibroBiologics?
- FibroBiologics was founded by Pete O'Heeron in 2021.
- How much funding has FibroBiologics raised?
- FibroBiologics has disclosed $10.7M raised across 5 of its 6 known rounds.
- Where is FibroBiologics headquartered?
- FibroBiologics is headquartered in Houston, US.